• Ionis partner Biogen plans to advance tau-targeting antisense drug diranersen into Phase 3 development for early Alzheimer’s disease.
• Phase 2 CELIA showed 50%-65% mean reductions in CSF total tau across doses; tau PET substudy showed decreases across regions.
• At 18 months, the 60 mg every-six-month regimen showed a 26% slowing on CDR-SB versus placebo; the study missed its primary endpoint.
• Safety profile was generally tolerable; most adverse events were mild to moderate; ARIA was not anticipated based on mechanism.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260714961307) on July 14, 2026, and is solely responsible for the information contained therein.